The growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, more than doubled revenues in FY2014 and FY2015 and has done so again at the recent half year results, with income of €9.06m recognised in the six months to June 2016. EBITDA from continuing operations was up more than fourfold to €0.4m and the balance sheet remains strong with period end cash of
05 Oct 2016
Revenues double again. Innovenn sale agreed. 2017 upgraded.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Revenues double again. Innovenn sale agreed. 2017 upgraded.
hVIVO plc (HVO:LON) | 29.0 0 0.0% | Mkt Cap: 197.3m
- Published:
05 Oct 2016 -
Author:
Derren Nathan -
Pages:
6
The growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, more than doubled revenues in FY2014 and FY2015 and has done so again at the recent half year results, with income of €9.06m recognised in the six months to June 2016. EBITDA from continuing operations was up more than fourfold to €0.4m and the balance sheet remains strong with period end cash of